Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Revolution Medicines

Stocks Generating Improved Relative Strength: Revolution Medicines

Revolution Medicines shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Revolution Crashes 34% On A Flop In Pancreatic Cancer Treatment. But There's A Silver Lining.

Revolution Crashes 34% On A Flop In Pancreatic Cancer Treatment. But There's A Silver Lining.

Biotech stock Revolution Medicines collapsed Monday after unveiling disappointing test results for an experimental cancer treatment.

Investors Business Daily

Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90

Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90

Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Revolution Medicines's Return On Capital Employed Overview

Revolution Medicines (NASDAQ:RVMD) brought in sales totaling $7.58 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 9.44%, resulting in a loss of $57.65 million.

Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022

Revolution Medicines's Earnings Outlook

Revolution Medicines (NASDAQ:RVMD) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Revolution Medicines will report an earnings per share (EPS) of $-0.77.

Children's Place And 2 Other Stocks Bought By Insiders

Although US stock futures traded higher this morning on Friday, there were a few notable insider trades.

inkl

Read news from The Economist, FT, and more,
with one subscription

Organisations

B of A Securities

Ollie Bargain Outlet

Hewlett Packard

Mirati rapeutics

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

246,313 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play